Lilly, Biolojic to develop antibody therapies for diabetes treatment

Eli Lilly and Company has signed a research collaboration and license agreement with Biolojic Design to discover and develop therapies for diabetes treatment. Under the deal, Biolojic’s artificial

The post Lilly, Biolojic to develop antibody therapies for diabetes treatment appeared first on Pharmaceutical Business review.

This is not a CAPTIS article. Originally, it was published here.